STOCK TITAN
  1. Home
  2. News
  3. ALLR

Allarity Therapeutics, Inc. - ALLR STOCK NEWS

Welcome to our dedicated page for Allarity Therapeutics news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity Therapeutics stock.

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. Founded in 2012, this innovative company is committed to unlocking the potential of new oncology products and rescuing failed drugs. Through its proprietary Drug Response Predictor (DRP®) technology, Allarity enhances patient selection and improves clinical outcomes in oncology.

Allarity boasts an impressive pipeline of in-licensed oncology therapeutics targeting difficult-to-treat cancers. Its lead product, stenoparib, a novel PARP/Tankyrase dual inhibitor, is currently being tested in advanced ovarian cancer patients. The DRP® companion diagnostic plays a crucial role in identifying patients who will benefit most from stenoparib, thereby increasing therapeutic efficacy and improving patient outcomes.

Recent achievements include significant advancements in their clinical trials, strategic financial restructurings, and compliance with Nasdaq listing requirements. The company's strategic pivot focuses on accelerating stenoparib's development, driven by promising Phase 2 trial data showing tumor shrinkage and long-term disease stability in heavily pre-treated ovarian cancer patients.

Allarity operates with research facilities in Denmark and a headquarters in the United States, underscoring its commitment to addressing significant unmet medical needs in cancer treatment. The company maintains an active presence in the clinical-stage pharmaceutical landscape, continually striving to develop novel personalized cancer treatments.

Visit www.allarity.com for more information and follow Allarity on LinkedIn and Twitter.

News

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Rhea-AI Summary
Allarity Therapeutics, Inc. announces a 1-for-20 reverse stock split to comply with Nasdaq's bid price requirement and operational benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
stock split
-
News

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Rhea-AI Summary
Allarity Therapeutics, Inc. announces a strategic pivot to focus on advancing stenoparib in advanced recurrent ovarian cancer, based on promising Phase 2 trial data. The company shifts resources to accelerate stenoparib development, deprioritizing IXEMPRA® and dovitinib. The decision aims to address an unmet medical need, reduce costs, and align with the growing PARP inhibitor market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
News

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Rhea-AI Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR) receives a formal extension until April 24, 2024, to regain compliance under Nasdaq Listing Rules. The company has presented a strategic plan to address compliance deficiencies, focusing on achieving a stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 per share for 10 consecutive business days. The plan includes cost reduction, liability conversion, and seeking additional capital to strengthen financial position and operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.25%
Tags
none
News

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
Allarity Therapeutics, Inc. reported significant advancements in personalized cancer treatments in 2023, with a focus on stenoparib for advanced ovarian cancer. The company reduced net loss from operations by 50% and net loss by 26%. Key highlights include the appointment of Thomas Jensen as Interim CEO, data showing clinical benefit in ovarian cancer trials, and engagement of Jeremy Graff, Ph.D. as an Executive Advisor. Anticipated milestones for 2024 include the disclosure of interim data from the Phase 2 clinical trial of stenoparib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
earnings
-
News

Allarity Therapeutics to Present at Biomarkers 2024

Rhea-AI Summary
Allarity Therapeutics, Inc. has been invited to present at Biomarkers 2024, showcasing their innovative work on the Drug Response Predictor (DRP®) companion diagnostics platform. The CEO, Thomas Jensen, will discuss the application of DRP® in an ongoing ovarian cancer trial, aiming to identify patients likely to benefit from treatment. The company's presentation will shed light on their cutting-edge personalized cancer treatment approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.08%
Tags
conferences
-
News

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Rhea-AI Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced a leadership transition with the appointment of Thomas H. Jensen as Interim CEO and the engagement of Jeremy R. Graff, Ph.D., as an Executive Advisor. Jensen brings two decades of experience and expertise to his new role, and Dr. Graff has over 25 years of experience in the biotech and pharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
management
News

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

Rhea-AI Summary
Allarity Therapeutics, Inc. (Nasdaq: ALLR) announces encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer. Of the five evaluable patients, one experienced a complete response, and the other four demonstrated stable disease. The protocol change from once-daily to twice-daily dosing has shown early signs of clinical benefit in all cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
clinical trial
-
News

Allarity Therapeutics to Present at Biomarkers Europe 2023

Rhea-AI Summary
Allarity Therapeutics, Inc. has been invited to present at Biomarkers Europe 2023, focusing on the development of drug-specific companion diagnostics for oncology therapeutics. They will also participate in a panel discussion with speakers from Merck and Roche. Additionally, the company will attend the ThinkEquity Conference in New York and is open to discussing business development opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
conferences
-
News

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology

Rhea-AI Summary
Allarity Therapeutics gaining momentum with positive milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
clinical trial
News

PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib

Rhea-AI Summary
Allarity Therapeutics publishes clinical validation of drug-specific companion diagnostic for dovitinib in renal cell carcinoma (RCC) patients, demonstrating improved clinical benefit compared to unselected patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.35%
Tags
none

FAQ

What is the current stock price of Allarity Therapeutics (ALLR)?

The current stock price of Allarity Therapeutics (ALLR) is $1.015 as of December 24, 2024.

What is the market cap of Allarity Therapeutics (ALLR)?

The market cap of Allarity Therapeutics (ALLR) is approximately 4.5M.

What does Allarity Therapeutics specialize in?

Allarity Therapeutics specializes in developing personalized cancer treatments using their Drug Response Predictor (DRP®) technology to enhance patient selection and improve clinical outcomes.

What is DRP® technology?

The Drug Response Predictor (DRP®) is a companion diagnostic tool that screens patients based on their cancer's gene expression signature to identify those most likely to benefit from specific oncology drugs.

What are the main products in Allarity Therapeutics’ pipeline?

Allarity Therapeutics' pipeline includes stenoparib, a novel PARP/Tankyrase dual inhibitor for advanced ovarian cancer, as well as other formulations like Dovitinib and Ixempra.

Where is Allarity Therapeutics headquartered?

Allarity Therapeutics is headquartered in the United States with a research facility in Denmark.

How has Allarity Therapeutics recently improved its financial standing?

Allarity has taken steps to regain compliance with Nasdaq listing requirements, including restructuring its financials, raising new equity, and reducing costs, resulting in a strengthened financial position.

What recent achievements has Allarity Therapeutics announced?

Recent achievements include significant clinical trial progress with stenoparib, achieving Nasdaq compliance, and strategic financial restructuring to support further development.

How does stenoparib work?

Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, which helps in blocking Wnt pathway activation and shows promise as a therapeutic for advanced ovarian cancer.

What are the benefits of using the DRP® companion diagnostic?

By using the DRP® companion diagnostic, Allarity can select patients with a high likelihood of benefiting from specific drugs, thus increasing therapeutic efficacy and improving patient outcomes.

Has Allarity Therapeutics regained compliance with Nasdaq’s listing requirements?

Yes, Allarity Therapeutics has regained compliance with Nasdaq’s minimum bid price and equity requirements, allowing continued listing and trading on Nasdaq.

What is the significance of the strategic pivot announced by Allarity Therapeutics?

The strategic pivot focuses on accelerating the development of stenoparib, driven by promising clinical data, and aims to address unmet medical needs in advanced ovarian cancer, potentially leading to regulatory approval.

Stock ALLR logo
Allarity Therapeutics, Inc.

Nasdaq:ALLR

ALLR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ALLR Stock Data

4.50M
4.26M
12.32%
2.21%
12.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON